Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer

We evaluated the survival benefit, safety, feasibility, and tolerability of dose-dense (DD) adjuvant chemotherapy with epirubicin and paclitaxel for women with node-positive primary breast cancer. Randomised patients (n=216) received DD or conventional-schedule (CS) chemotherapy. Dose-dense regimen...

Descripción completa

Detalles Bibliográficos
Autores principales: Kümmel, S, Krocker, J, Kohls, A, Breitbach, G-P, Morack, G, Budner, M, Blohmer, J-U, Elling, D
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361407/
https://www.ncbi.nlm.nih.gov/pubmed/16622463
http://dx.doi.org/10.1038/sj.bjc.6603085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361407/
https://www.ncbi.nlm.nih.gov/pubmed/16622463
http://dx.doi.org/10.1038/sj.bjc.6603085

Ejemplares similares